Pharvaris (PHVS, Financial) has unveiled new insights at the 14th C1-Inhibitor Deficiency and Angioedema Workshop, highlighting key findings about deucrictibant. The company's recent analyses underscore the consistent clinical profile of deucrictibant in both preventive and immediate-use scenarios. The treatment's ability to deliver a rapid and lasting response in acute settings, along with more than 18 months of sustained attack reduction in preventative use, suggests significant potential for treating bradykinin-mediated angioedema.
The company is actively advancing its clinical program, with two pivotal data releases anticipated within the next 18 months, which could further cement deucrictibant’s role in therapy for angioedema. These developments are part of Pharvaris's ongoing efforts to solidify the treatment's efficacy and broaden its application in various clinical settings.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 10 analysts, the average target price for Pharvaris NV (PHVS, Financial) is $33.36 with a high estimate of $55.27 and a low estimate of $14.07. The average target implies an upside of 102.20% from the current price of $16.50. More detailed estimate data can be found on the Pharvaris NV (PHVS) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, Pharvaris NV's (PHVS, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
